Leonard Zehr, Author at BioTuesdays

Feature

180 Life Sciences focused on one of largest drivers of disease: inflammation

180 Life Sciences (NASDAQ:ATNF) has three families of novel biologic drugs in synchronized stages of development, addressing separate areas of inflammation, fibrosis and pain, for which there are no effective therapies.

March 29, 2022

Markets

Maxim starts Longeveron at buy; PT $14

Maxim Group initiated coverage of Longeveron (NASDAQ:LGVN) with a “buy” rating and $14 price target. The stock closed at $6.52 on March 23. Longeveron is developing a medicinal signaling cell therapy, Lomecel-B, for...

March 24, 2022

Feature

First Wave developing targeted, non-systemic therapies for GI diseases

First Wave BioPharma (NASDAQ:FWBI) is advancing multiple clinical-stage programs built around its two proprietary technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and a...

March 22, 2022

Feature

Transforming biologic drug discovery with Sean McClain of Absci

As CEO and founder of Absci (NASDAQ:ABSI), a drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, Sean McClain has come a long way in the...

March 15, 2022

Markets

HCW starts Esperion at buy; PT $22

H.C. Wainwright initiated coverage of Esperion Therapeutics (NASDAQ:ESPR) with a “buy” rating and price target of $22. The stock closed at $4.57 on March 9. Esperion is a commercial-stage company focused on development...

March 10, 2022

Feature

Ampio to seek FDA agreement on modified intent-to-treat BLA in severe OAK

Ampio Pharmaceuticals (NYSE American:AMPE), citing a significant impact from COVID-19 on its second confirmatory Phase 3 trial of Ampion for the treatment of severe osteoarthritis of the knee (OAK), hopes to meet with...

March 8, 2022

Feature

Precigen advancing pipeline of gene and cell therapies in I-O, autoimmune, infectious disorders

Precigen (NASDAQ:PGEN) is advancing a pipeline of next generation gene and cell therapies using precision technology in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.

March 1, 2022

Markets

Cantor starts Affimed at OW; PT $12

Cantor Fitzgerald initiated coverage of Affimed N.V. (NASDAQ:AFMD) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.23 on Feb. 22. Affimed, which is one of Cantor’s top picks for...

February 23, 2022

Feature

Palisade Bio guarding against post-operative disruption of GI function

Palisade Bio (NASDAQ:PALI) is advancing therapies that help patients with acute and chronic GI complications, stemming from post-operative tissue damage, to speed recovery and reduce hospital stays.

February 22, 2022

Markets

Cantor starts vTv at OW; PT $5

Cantor Fitzgerald launched coverage of vTv Therapeutics (NASDAQ:VTVT) with an “overweight” rating and 12-month price target of $5. The stock closed at 71 cents on Feb. 17. vTv is developing novel orally administered...

February 18, 2022

Author - Leonard Zehr

180 Life Sciences focused on one of largest drivers of disease: inflammation

Maxim starts Longeveron at buy; PT $14

First Wave developing targeted, non-systemic therapies for GI diseases

Transforming biologic drug discovery with Sean McClain of Absci

HCW starts Esperion at buy; PT $22

Ampio to seek FDA agreement on modified intent-to-treat BLA in severe OAK

Precigen advancing pipeline of gene and cell therapies in I-O, autoimmune, infectious disorders

Cantor starts Affimed at OW; PT $12

Palisade Bio guarding against post-operative disruption of GI function

Cantor starts vTv at OW; PT $5

Subscribe